Eighteen patients with glossodynia were treated with Flutazolam. Excellent effects were seen in 27.8%, marked effects in 22.2%, slight effects in 22.2%, and no effect in 27.8% of the patients. Only one case experienced drowsiness. With regard to the relationship between sex or age and clinical efficacy, effective cases were seen more frequently in female than in male patients, as well as in elderly patients 50 years old and over. It was observed that the group administered a daily dose of 6 capsules responded better than did the group administered 3 capsules. The group administered only this drug showed slightly lower improvement than the group administered other drugs simultaneously, such as a steroid ointment, although half of the cases showed slight or better improvement, including excellent.
Low neurotic tendency cases determined by the CMI test showed better results than hign cases, and cases with decreased CMI-area showed better results than those with increased or no change. Better effects were observed in cases with decreased physical subjective symptoms, and psychiatric subjective symptoms showed obviously better results than in those with increased or no change, so that the relationship between clinical effects may be explained by more sensitive detection rather than CMI-area changes in the CMI test. Stage I-II patients having a high degree of anxiety determined by the MAS test showed little improvement, while on the other hand, stage III-IV patients with a low degree of anxiety showed much improvement. In the stage III-IV patients, no relationship between the clinical effect and the change in anxiety score was seen. For stage I-II of the high anxiety group, clinical efficacy was observed only in cases with a decreased anxiety score, so an extremely strong relationship between the clinical effect and the change in anxiety score can be assumed.
From the above results, it is concluded that Flutazolam is useful for the treatment of glossodynia.

抄録全体を表示

1) Following 1-h i.v. drip infusion with Ceftriaxone (CTRX) at 33 mg/kg into NZW rabbits, the serum level remained high for a long period of time : The C_max was 67.761 mcg/ml and the T_1/2 4.189 h. The proportion of oral tissue level to serum level was 41 to 95% at the peak and 42 to 119% 10 h post-dose.
2) With administration of CTRX at 1 or 2 g once daily into 96 patients with osteitis or cellulitis of the jaw, both acute suppurative infections in the oral surgery field, the clinical efficacy rate was 86.8% (91/96) by judging the numerical rating on the 3rd day and 84.4% according to the evaluation by the doctor in charge.
3) Adverse reactions were observed in 3 patients (3%) . Drug administration was discontinued in 1 of the 3 due to nausea and fever which appeared immediately after the i.v. injection. In the other 2, natural remission was observed during the course of continued administration.
4) In clinical laboratory tests, abnormal parameter values were detected in 16% (12 patients) ; liver dysfunction suggested by an increase in transaminase, etc. in 10, an increase in BUN in 1 and an increase in eosinophils in 1.
5) CTRX is characterized by a broad antibacterial spectrum, long half-life, favourable tissue transfer and enough clinical efficacy with once-a-day dosing to enable outpatient treatment. When treating with the drug, however, patients should be carefully observed for liver function.

抄録全体を表示

The effects and complications associated with cisplatin and peplomycin combination chemotherapy (CP therapy) are reported. Nine patients with head and neck cancer were treated as follows : cisplatin (75 mg/body) was administered by intravenous infusion continuously for 24 h, followed by continuous peplomycin (5 mg/body) intravenous infusion for 5 h per day for 2 or 6 days.
A complete response (CR) was attained in 2 patients and a partial response (PR) in 5. Complications observed were : leukocytopenia (7), anemia (6), nausea or vomiting (4), renal disorder (4), fever (2), increased serum transaminase levels (6) and hair loss (3) .
It is concluded that CP therapy was effective and safe as neo-adjuvant treatment for patients with head and neck cancer.

抄録全体を表示

Although the number of patients with psychosomatic disorders in the oral cavity has increased steadily during recent years, no definite therapeutic method has been established. In this study, we prescribed Etizolam (Depas^®), a thienodiazepine derivative, to patients with neurotic halitosis and glossodynia, both of which are psychosomatic disorders of the oral cavity, in order to test the efficacy of the drug. Etizolam was prescribed to 20 patients with neurotic halitosis with the aims of decreasing tension arising from interpersonal contact and increasing sociability by improving autonomic nervous system functioning. The present drug was effective in more than 80% of the cases. The same drug was prescribed to 20 cases with glossodynia with the aim of increasing the pain threshold and suppressing intrapunitive tendencies; it showed effectiveness in more than 85% of the cases. As can be seen by the above results, Etizolam was found to be highly effective in patients with oral cavity psychosomatic disorders.

抄録全体を表示

Comparative studies were conducted on 2 circulatory stability parameters during surgery, postoperative partial pressure of blood gas and the induction and arousal speeds, in cases undergoing oral surgery. Modified NLA methods were applied to 2 groups, Butorphanol (0.04 mg/kg) with Flunitrazepam (0.015mg/kg) or Pentazocine (1.0 mg/kg) with Fluni-trazepam (0.015 mg/kg) . No case in the Butorphanol group required volatile anesthetic agents, whereas additional administration was necessary in 3 cases in the Pentazocine group. No significant differences were observed between the 2 groups with respect to induction and arousal speeds. The postoperative Pao₂ level was significantly lower in both groups, although there were no significant difference in terms of the degree. Thus, it is concluded that the modified NLA method with Butorphanol and Flunitrazepam showed high circulatory stability during surgery, and that it is more useful than the modified NLA method with Pentazocine and Flunitrazepam.

抄録全体を表示

This study was carried out in order to investigate the effects of analgesics on threshold values evaluated by electrical teeth stimulation using an autoelectric dental pulp tester.
The subjects were 12 volunteers, including 6 males and 6 females, all in good health (ages, 23 to 28 years old) . A healthy central maxillary incisor tooth was chosen for evaluation. Three kinds of drugs were administered, floctafenine, loxoprofen sodium and placebo (lactose) . Threshold values were examined before and at 15 and 30 min, and 1 and 3 h after oral administration. Results obtained were as follows.
1) The threshold values of floctafenine at 1 h were higher than those of the same drug before administration (p<0.10) and placebo at 1 h (p<0.05) .
2) Oral administration of loxoprofen sodium and placebo did not have significant effects on the dental pulp threshold values.

抄録全体を表示

The analgesic and anti-inflammatory effects and safety of a 0.15% benzydamine gargle preparation (NIK-237) were studied in 87 patients with various kinds of oral mucosal diseases. The following results were obtained:
1) The overall improvement rating indicated that 40.2% were “moderately improved” and that 79.3% were “slightly effective.” Relatively high improvement ratings were observed for chronic recurrent aphtha, erosive or ulcerative stomatitis and viral stomatitis.
2) Side effects were observed in 13 patients (14.9%), in which 12 cases complained of numbness in the oral cavity and 1 complained of nausea immediately after gargling. No abnormality was recognized in the oral mucosa upon inspection and no systemic symptoms caused by gargling were observed.
3) For the usefulness rating, “fairly useful” was judged to be 36.8% and “slightly useful” 77%. High usefulness was recognized for chronic recurrent aphtha, erosive or ulcera-tive stomatitis and viral stomatitis.
4) An improved rating for the respective items way relatively high for pain during palpation and eating, and burning pain. Furthermore, when comparing “evaluation through whole day” and “evaluation immediately after drug administration, ” the latter tended to be superior. The patients impression was also better in the latter.

抄録全体を表示

The analgesic effects and safety of a 0.15% benzydamine gargle preparation (NIK-237) on aphtha and lichen planus lesions were investigated in a controlled study using placebo. The clinical effects of each drug were evaluated in 149 patients (NIK-237-treated group: 75, placebo-treated group : 74), and the following results were obtained.
1) Analgesic effect according to the judgment of the physician in charge : The NIK-237-treated group was superior, with a significant difference being observed (p<0.05) compared to the placebo-treated group.
2) Analgesic effect by scoring: The NIK-237-treated group was superior, with a significant difference being observed (p<0.05) compared to the placebo-treated group.
3) Overall safety rating : Both groups were judged to produce no side effects.
4) Usefulness : The NIK-237-treated group was superior, with a significant difference being observed (p<0.05) compared to the placebo-treated group.
5) Improvement rating of spontaneous pain with time : The NIK-237-treated group was superior (p<0.05) or tended to be superior (p<0.1) to that of the placebo-treated group 15, 60 and 120 minutes after administration of the drugs.
6) Effect on pain at the time of eating : The NIK-237-treated group tended to be superior (p<0.1) to that of the placebo-treated group.
From the above results, it is concluded that NIK-237 is highly useful for the treatment of oral mucosal diseases.

抄録全体を表示

The actual situation of the dental drug use in 17 hospitals of dental college and university during the last three and half years was investigated. The numbers of drugs investigated were 148 which were 117 drugs only for dental therapy listed in the drug price list (part 4) and 12 drugs for gargles and 19 drugs for oral use, appeared in the drug list of general medical use. Twenty four drugs in 148 of dental drugs had not been on the market because of no production. The average number of drugs used in each hospital was 38 ranging 27 to 56.
The drug preparations such as camphorated-phenol, formalin-cresol and dental iodine glycerin were prepared in the hospital pharmacy.
It was confused to register all the chemicals used in dental practices as the dental drug or dental material.
The renewal of the package inserts ordered by the Ministry of Welfare was almost com-pleted in dental drugs but its retaining rate in each hospital pharmacy was only about 58%.

抄録全体を表示